Circulating tumor cells (CTC) and circulating endothelial cells (CEC) in patients (pts) receiving adjuvant bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nab-paclitaxel (nab-P) for early-stage breast cancer (ESBC) Meeting Abstract

  

Authors:	Melisko, M. E.; Greenberg, S.; Dickler, M. N.; Moasser, M. M.; Scott, J. H.; DeLuca, A. N.; Moore, D. H.; Hudis, C.; Park, J. W.; Rugo, H. S.
Abstract Title:	Circulating tumor cells (CTC) and circulating endothelial cells (CEC) in patients (pts) receiving adjuvant bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nab-paclitaxel (nab-P) for early-stage breast cancer (ESBC)
Meeting Title:	46th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	28
Issue:	15 Suppl.
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2010-05-20
Start Page:	86s
Language:	English
ACCESSION:	WOS:000208852002413
DOI:	10.1200/jco.2010.28.15_suppl.579
PROVIDER:	wos
Notes:	Meeting Abstract: 579 -- S -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/129512